CUSIP: 62921N105
What is CUSIP 62921N105?
CUSIP 62921N105 identifies NGM - NGM BIOPHARMACEUTICALS INC - COM in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2024 Q2 | 0 | $0 | -$54,723,051 | 0 | |
| 2024 Q1 | 34,591,504 | $54,999,572 | -$5,774,913 | $1.59 | 70 |
| 2023 Q4 | 41,122,220 | $35,321,273 | -$5,621,280 | $0.86 | 79 |
| 2023 Q3 | 47,286,277 | $50,601,674 | -$2,234,506 | $1.07 | 91 |
| 2023 Q2 | 47,982,303 | $124,272,246 | -$3,211,886 | $2.59 | 101 |
| 2023 Q1 | 47,197,224 | $192,506,190 | -$4,758,058 | $4.08 | 121 |
| 2022 Q4 | 49,595,426 | $248,961,789 | -$44,837,115 | $5.02 | 123 |
| 2022 Q3 | 52,764,683 | $690,130,864 | +$70,574,503 | $13.08 | 124 |
| 2022 Q2 | 47,362,672 | $607,192,137 | -$21,648,197 | $12.82 | 116 |
| 2022 Q1 | 48,055,378 | $732,837,689 | +$12,060,151 | $15.25 | 111 |
| 2021 Q4 | 47,064,729 | $833,490,515 | +$27,920,648 | $17.71 | 113 |
| 2021 Q3 | 29,843,007 | $627,606,289 | +$49,369,343 | $21.02 | 117 |
| 2021 Q2 | 39,319,777 | $775,411,946 | -$8,938,336 | $19.72 | 105 |
| 2021 Q1 | 39,267,121 | $1,141,407,737 | +$164,908,439 | $29.07 | 102 |
| 2020 Q4 | 33,339,501 | $1,010,134,414 | +$27,899,518 | $30.30 | 87 |
| 2020 Q3 | 30,436,879 | $484,291,987 | +$5,934,350 | $15.91 | 78 |
| 2020 Q2 | 30,000,648 | $592,206,185 | +$34,248,759 | $19.74 | 78 |
| 2020 Q1 | 32,276,256 | $397,969,642 | +$33,512,358 | $12.33 | 71 |
| 2019 Q4 | 12,426,425 | $229,759,386 | +$44,167,440 | $18.49 | 56 |
| 2019 Q3 | 26,361,341 | $365,102,529 | +$1,382,126 | $13.85 | 49 |
| 2019 Q2 | 26,070,117 | $381,660,468 | +$381,660,000 | $14.64 | 46 |